Free Trial
NASDAQ:PULM

Pulmatrix (PULM) Stock Price, News & Analysis

Pulmatrix logo
$7.69 +0.88 (+12.98%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Pulmatrix Stock (NASDAQ:PULM)

Key Stats

Today's Range
$6.99
$8.41
50-Day Range
$5.39
$7.74
52-Week Range
$1.72
$10.40
Volume
76,797 shs
Average Volume
132,682 shs
Market Capitalization
$28.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Pulmatrix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

PULM MarketRank™: 

Pulmatrix scored higher than 10% of companies evaluated by MarketBeat, and ranked 908th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Pulmatrix.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pulmatrix is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pulmatrix is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pulmatrix has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pulmatrix's valuation and earnings.
  • Percentage of Shares Shorted

    0.65% of the float of Pulmatrix has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmatrix has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmatrix has recently decreased by 5.56%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pulmatrix does not currently pay a dividend.

  • Dividend Growth

    Pulmatrix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.65% of the float of Pulmatrix has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmatrix has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmatrix has recently decreased by 5.56%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Pulmatrix has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Pulmatrix this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pulmatrix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.62% of the stock of Pulmatrix is held by insiders.

  • Percentage Held by Institutions

    Only 11.84% of the stock of Pulmatrix is held by institutions.

  • Read more about Pulmatrix's insider trading history.
Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Stock News Headlines

Alpha Zone Pro beats 6 traditional indicators?
I’m not trying to toot my own horn or anything like that… But Matt and I might have just created the most innovative day trading system for the SPY out there. I mean consider this… How many technical indicators can tell when the SPY will likely breakout or breakdown – before it happens? The RSI… Bollinger bands… Trend lines… Fibonacci… Heck! Even the Elliot wave or MACD. How many can tell – with near 100% precision – the SPYs exact move for the day? But just this week alone, Alpha Zone Pro has successfully pointed us to the exact direction the SPY was going to move.
See More Headlines

PULM Stock Analysis - Frequently Asked Questions

Pulmatrix's stock was trading at $6.98 on January 1st, 2025. Since then, PULM shares have increased by 10.9% and is now trading at $7.74.
View the best growth stocks for 2025 here
.

Pulmatrix, Inc. (NASDAQ:PULM) released its quarterly earnings results on Thursday, May, 15th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter. Pulmatrix had a negative net margin of 96.51% and a negative trailing twelve-month return on equity of 45.97%.

Pulmatrix's stock reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional shareholders of Pulmatrix include SBI Securities Co. Ltd. (1.43%).
View institutional ownership trends
.

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmatrix investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), GE Aerospace (GE), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

Last Earnings
5/15/2025
Today
5/27/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PULM
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.12 million
Pretax Margin
-96.51%

Debt

Sales & Book Value

Annual Sales
$1.92 million
Price / Cash Flow
N/A
Book Value
$4.93 per share
Price / Book
1.57

Miscellaneous

Free Float
3,629,000
Market Cap
$28.25 million
Optionable
Not Optionable
Beta
1.38

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:PULM) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners